Kornimate/medical-research-clean huggingface dataset:
contrast nephropathy prevention with n-acetylcysteine in acute myocardial infarction

Conditions: Contrast-Induced Nephropathy; Acute Myocardial Infarction

Summary: patients with acute myocardial infarction undergoing primary angioplasty are at high risk for renal injury due to the toxic effect of contrast agents. patients developing renal dysfunction after primary angioplasty have worse outcome. to investigate the role of the antioxidant n-acetylcysteine (nac) in preventing renal injury in angioplasty, we randomized 352 consecutive patients undergoing primary angioplasty into three groups: the first group received nac at standard dose (nac group, 600 mg i.v. bolus before primary angioplasty, followed by oral 600 mg twice daily for the following 48 hours; n=115), the second group received nac at double dose (dd-nac group; 1,200 mg i.v. bolus and oral 1,200 mg twice daily for 48 hours; n=118), and the last group received placebo (controls; n=119).


Eligibility criteria:
inclusion criteria:consecutive patients admitted to the coronary care unit for st-segment elevation acute myocardial infarction undergoing primary angioplasty. patients were included if they presented within 12 hours (18 hours for acute myocardial infarction complicated by cardiogenic shock) from the onset of symptoms. - exclusion criteria:patients in chronic peritoneal or hemodialytic treatment and those with known allergy to n-acetylcysteine. -

Keywords: contrast-induced nephropathy acute myocardial infarction primary coronary angioplasty
evaluation of efficacy and safety of prolia in subjects of male osteoporosis in mainland china

Conditions: Osteoporosis

Summary: the primary objective of this study is to evaluate the efficacy of prolia on lumbar spine bmd at 12 months.


Eligibility criteria:
inclusion criteria: * ambulatory chinese men aged ≥ 30 years and ≤ 90 years old at the time of signing the informed consent. * men at the time of screening will be required to have lumbar spine or total hip bmd t-score ≤ -2.5 or t-score ≤ -1.5 and a history of a fragility fracture. * have to have at least two intact vertebrae at baseline (l1-l4). exclusion criteria: * any condition that could affect bone metabolism such as paget's disease of bone, osteomalacia including secondary causes of osteoporosis (subjects with low testosterone levels are allowed). * hyper- or hypothyroidism; however, stable subjects, in the investigator's opinion, on thyroid hormone replacement therapy are allowed. * participants with a history of any cancer (cured basal cell or squamous cell cancers are allowed). * any condition that in the opinion of the investigator would not allow the subject to complete 1 year study and comply with the requirement of the study protocol. * hypogonadism requiring testosterone replacement therapy unless on a stable dose for at least 12 months. * administration of intravenous bisphosphonate, or fluoride (except for dental treatment) or strontium ranelate. systemic glucocorticoids: ≥ 7.5 mg prednisone equivalent per day for more than 14 days within 3 months before randomization. any bone anabolic treatment within 1 year. anabolic steroids or testosterone: any use within 6 months before randomization. * oral bisphosphonates treatment. * known to have tested positive for human immunodeficiency virus, hepatitis c virus, hepatitis b surface antigen, or cirrhosis of the liver. * received any solid organ or bone marrow transplant or is on chronic immunosuppression for any reason. * oral/dental conditions that would require an intervention including tooth extraction during the course of the study and invasive dental work (per local oral surgeon's assessment) planned in the next 12 months. * any prior use of products containing denosumab. * currently receiving treatment in another investigational device or drug study, or less than 1 month since ending treatment on another investigational device or drug study(ies). other investigational procedures while participating in this study are excluded. * vitamin d levels \< 20 ng/ml (subjects are allowed into the study after vitamin d levels are corrected and subjects re-screened). * albumin-adjusted serum calcium levels \ 10.5 mg/dl.

Keywords: prolia denosumab amg 162 osteoporosis
an observational study to evaluate the efficacy of biweekly romiplostim in adult patients with itp

Conditions: Immune Thrombocytopenia

Summary: the aim of this study is to evaluate the efficacy of romiplostim administered at every other week in itp patients who attained stable platelet counts ≥ 50 x 109/l for 4 consecutive weeks after weekly doses of romiplostim.

regarding the determination of appropriate dose, it is well known that romiplostim resulted in dose-dependent increases in platelet counts, but required dose for raising platelet count is variable between individuals according to each patient's ability to eliminate serum romiplostim. because of this variability, after administration of initial 1mcg/kg of romiplostim, dose adjustment is recommended based on the platelet response to given dose of romiplostim. however, the optimal dose interval of romiplostim has rarely been studied. in pivotal studies, romiplostim was administered on a weekly schedule, and based on these studies, one dose at every week is being widely used. in one study in which itp patients received weekly subcutaneous doses of romiplostim at a range from 3 to 15mcg/kg, half life of romiplostim was estimated from 1 to 34 days, suggesting that lengthening the interval between doses more than a week can be potentially possible in some patients.

Eligibility criteria:
inclusion criteria: 1. subject has an ability to provide written informed consent prior to participating to the study 2. subject is male or female ≥ 18 years of age 3. subject has a diagnosis of immune thrombocytopenia (itp) per the american society of hematology guidelines. 4. subject received at least 1 prior therapy for itp including corticosteroids, immunoglobulin, or splenectomy, but had an insufficient response to any of these treatment (plt count should be \< 30x109/l before romiplostim initiation.) 5. if subject had ever received tpo receptor agonist before, the patient can participate this study only after 8 weeks' wash out period exclusion criteria: 1. subject has a history of hematological malignancy, myeloproliferative disorder, myelodysplastic syndrome (mds), or bone marrow stem cell disorder 2. subject has participated in any study evaluating peg-rhumgdf, recombinant human thrombopoietin (rhutpo), or related platelet product within 8 weeks 3. subject has a known hypersensitivity to any recombinant e coli-derived product 4. subject has received any therapeutic drug or device that is not approved by the local regulatory health agency for any indication within 4 weeks of screening 5. subject is of reproductive potential and is not using adequate contraceptive precautions, in the judgment of the investigator 6. subject is pregnant or breast feeding
the determining statin intolerance for rosuvastatin (desifor) trial

Conditions: Cardiovascular Risk Factor; Cardiovascular Diseases; Adverse Effect

Summary: this study will enroll patients who previously were not able to tolerate being on a statin medication due to muscle-related side effects. research has shown that many people who have muscle symptoms on statin therapy do not experience the same side effects if they try it again later. this study is part of a larger effort to: * see how common it is for patients to still be intolerant of statin medication after trying it a second time; and * for those patients who do tolerate being on a statin after trying it a second time, see how common it is for them to still be taking the statin 3 months after completing the main part of the study. patients who agree to participate will be given a 5 month randomly allocated supply of statin and placebo and track their symptoms weekly.

this study is a single center, double-blinded randomized controlled trial for patients eligible for statin therapy by current guidelines, but not on statin therapy due to a history of statin intolerance. patients will be provided a "desifor" kit which includes 5 randomly allocated 4-week blister packs of capsules containing either 20mg of rosuvastatin or placebo. while blinded to treatment, patients will document the severity of musculoskeletal symptoms every week using a numerical scale. the primary endpoint will be the difference between the mean musculoskeletal symptom score while randomized to statin therapy compared to the mean score while on placebo. after completion of the study, the results will be unblinded and reviewed at a 6 month follow-up visit with the patient and, for patients with symptoms found to not correlate with statin therapy, a trial of non-blinded statin therapy over the next 3 months will be recommended. this study will serve as a pilot study to determine the feasibility and potential benefits of a larger multicenter trial with similar aims.

Eligibility criteria:
inclusion criteria: * adults age 21-75 years old * statin eligible according to the 2013 acc/aha cholesterol guidelines, including individuals with: * known ascvd * diabetes * ldl-c \> 190mg/dl * 10-year ascvd risk \>7.5% * statin intolerant * defined by discontinuation of at least 2 separate statins due to potential musculoskeletal side effects exclusion criteria: * women who are pregnant, nursing or attempting to become pregnant. * individuals deemed to be at very high cvd risk and therefore appropriate for a pcsk9 inhibitor including: * individuals with familial hypercholesterolemia with markedly elevated ldl-c levels * individuals with known ascvd and recurrent events * individuals who are not otherwise clinically indicated to take 20mg rosuvastatin * individuals who experienced severe reactions in the past, including: * rhabdomyolysis * severe myositis * anaphylaxis

Keywords: statin therapy prevention high ascvd risk
inspiratory flow using the osmohaler

Conditions: Asthma

Summary: the osmohalertm is a registered device in australia. it is used to deliver a dry powder a commercial preparation of mannitol registered as aridoltm to test if a person has irritable airways such as active asthma. the overseas regulatory authorities need to know that people of all ages can achieve an adequate inspiratory flow through this device during a controlled deep inspiration. adequate flow is generally regarded as greater than 30 litres per minute in children and 60 litres per minute in adults. the osmohalertm is a device with low resistance and is already in use in australia to deliver mannitol. however there is a need to document inspiratory flows through the device during a controlled deep inspiration. the protocol requires subjects to perform a controlled deep inspiration from the device on three or five occasions. no substance will be inhaled.


Eligibility criteria:
inclusion criteria: * has asthma or is healthy * aged 6 to 69 years inclusive * fev1 \>/= 70% predicted exclusion criteria: * has condition contraindicating performance of spirometrt

Keywords: asthmatic healthy
bilateral endoscopic thoracic t3 sympathectomy versus t3 radiofrequency ablation for primary palmar hyperhidrosis

Conditions: Primary Palmar Hyperhydrosis

Summary: primary hyperhidrosis disease is characterized by much more sweating above the needs for thermoregulation, which is worsen by increased temperature and emotional factors it can be seen in the palms of the hands, soles of the feet/ face and so on. hyperhidrosis usually starts since childhood and continuous throughout life aggravated by emotional stress or by high environmental temperature. many lines of treatment were tried such as anticholinergic drug, physiotherapy. endoscope thoracic sympathectomy and radio frequency with phenol injection.

interruption of intrathoracic sympathetic neural pathway surgically to treat hyperhidrosis by using video - thoracoscopy which has lead to explosion of minimally invasive technique for this issue. it's safe procedure and success rate in about 95% so it's result in this disease are rewarding. other technique will be studied in this current study is radiofrequency ablation it may be a good option for treatment of primary hyperhidrosis. when endoscope is not allowed. an early outcome is our primary target for comparing the two different techniques. treatment with radiofrequency can benefit patients specially young one because a lot of them refuse endoscopic sympathectomy with its special anesthetic consideration as one lung ventilation and sometimes patient left with intercostal tube for some days so it's considered difficult procedure and much more easy is radiofrequency but alone the results is not satisfactory so in this clinical trial endoscopic sympathectomy will be compared with radiofrequency ablation regarding to the early outcome for the two procedure in this clinical trial interruption of sympathetic chain was chosen at the level of t3 because at this level interruption involve only the sympathetic chain without any ganglion damage or compensatory sweating which was seen when the interruption of the level of t4.

Eligibility criteria:
inclusion criteria: * patients with primary palmar hyperhydrosis. * patients with american society classification 1 and 2. exclusion criteria: * patient refusal. * previous sympathectomy either endoscopic or by radiofrequency. * previous sternotomy operation.
study of tumor and blood samples from postmenopausal women with primary breast cancer enrolled on clinical trial can-ncic-ma27

Conditions: Breast Cancer

Summary: rationale: studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this research study is looking at tumor and blood samples from postmenopausal women with primary breast cancer enrolled on clinical trial can-ncic-ma27.

objectives: primary * to identify genetic variation, as measured by single nucleotide polymorphisms, that is associated with musculoskeletal adverse events in specimens from postmenopausal women with hormone receptor-positive primary breast cancer receiving adjuvant aromatase inhibitors and enrolled on clinical trial can-ncic-ma27. outline: this is a multicenter study. dna from tumor tissue and blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed invasive breast cancer * complete resection of primary tumor * stage i-iii (t1-3, n0-3, m0) disease * enrolled in clinical trial can-ncic-ma27. * no locally recurrent or metastatic breast cancer * hormone receptor status: * estrogen receptor- or progesterone receptor-positive disease patient characteristics: * postmenopausal status, defined as one of the following: * at least 60 years old * age 45-59 years with spontaneous cessation of menses for \> 12 months prior to chemotherapy or study randomization * age 45-59 years with cessation of menses for \ 34.4 iu/l) * age 45-59 years on hormone replacement therapy (hrt) and discontinued hrt at diagnosis of breast cancer and fsh level in the postmenopausal range (or \> 34.4 iu/l) * bilateral oophorectomy prior concurrent therapy: * see disease characteristics

Keywords: stage ia breast cancer stage ib breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer estrogen receptor-positive breast cancer progesterone receptor-positive breast cancer
sci pain app intervention study

Conditions: Spinal Cord Injuries; Chronic Pain

Summary: the purpose of this study is to find out if using an app is a feasible and acceptable treatment for chronic pain in persons with spinal cord injury. participants will have a 50% chance of being asked to listen to 10 minutes of audio-guided meditations using an app each day for six weeks, and a 50% chance of being asked to listen to 10 minutes of engaging and distracting presentations about topics of interest to the individual (ted talks) for six weeks. all participants will be asked to complete three online surveys about their emotional and physical health lasting 20-30 minutes (one when the participant first enters the study, one six weeks later, and another six weeks later). additionally, participants will be asked to complete brief (\<5 minute) online surveys once a week during the first six weeks of their participation. participation in this study is very low risk, and participants may not experience any personal benefit from their participation. participation in this study is entirely voluntary.


Eligibility criteria:
inclusion criteria: 1. are at least 18 years of age 2. have a traumatic sci of at least 6 months duration 3. have chronic pain \[defined as pain lasting at least 3 months with a pain intensity rating of 4 or higher on a 10-point visual analog scale\] 4. understand spoken and written english sufficiently to understand the goals, procedures, time involved, and the time involved in participation, participate in the intervention and complete study surveys. exclusion criteria: 1. have a significant visual or hearing impairment that limits their ability to participate in the app/computer-based intervention 2. lack access to and the ability to use a smart phone or smart tablet (e.g., ipad) 3. are unable to provide or obtain an email address for communication 4. practiced any kind of meditation more than once a week in the past 3 months
the clinical applications of d-type parastomal hernia repair surgery

Conditions: Hernia Repair; Stoma Reconstruction; Function and Appearance

Summary: during the period from february 2018 to february 2022, a study was conducted on patients with parastomal hernia.there were 23 patients who underwent repair surgery for d-type colostomy hernia, while 68 patients underwent traditional laparoscopic repair surgery for hernia.the inclusion criteria were: (1) preoperative diagnosis of parastomal hernia by ct scan; (2) underwent laparoscopic repair surgery or combined laparoscopic repair with abdominal wall and stoma reconstruction surgery.the exclusion criteria were: (1) occurrence of tumor recurrence and/or new tumors during the follow-up period; (2) death or loss to follow-up during the follow-up period.


Eligibility criteria:
inclusion criteria: (1) preoperative diagnosis of parastomal hernia by ct scan; (2) underwent laparoscopic repair surgery or combined laparoscopic repair with abdominal wall and stoma reconstruction surgery. exclusion criteria: (1) occurrence of tumor recurrence and/or new tumors during the follow-up period; (2) death or loss to follow-up during the follow-up period.
treatment of hepatocellular carcinoma: long-acting somatostatin plus percutaneous ethanol instillation (pei) versus long-acting somatostatin alone

Conditions: Carcinoma, Hepatocellular

Summary: hepatocellular carcinoma (hcc) is a consequence of liver cirrhosis. in early tumour stages, tumour resection or liver transplantation are therapeutic options; later tumour stages may be treated with locally ablative treatments such as percutaneous ethanol instillation (pei), transarterial chemoembolization (tace) or radio-frequency thermoablation. this randomized study investigates the effect of pei on survival of patients with hcc. all patients will receive hormonal treatment (long-acting somatostatin intramuscularly \[i.m.\]) and will be randomized for treatment with pei or no additional treatment.

this is a randomized two-arm parallel group study. * study group: pei + long-acting somatostatin * control group: long-acting somatostatin alone aims of the study: * does treatment with pei+ long-acting somatostatin prolong survival as compared to treatment with long-acting somatostatin alone? * can time to tumour progression be extended in patients treated with pei + long-acting somatostatin as compared to treatment with long-acting somatostatin alone?

Eligibility criteria:
inclusion criteria: * histologically-proven hepatocellular carcinoma * treatable with percutaneous ethanol instillation * inoperable tumour * age 18-85 years exclusion criteria: * liver cirrhosis child c * tumour diameter \> 8 cm

Keywords: carcinoma, hepatocellular, percutaneous ethanol instillation long-acting somatostatin
efficacy of platelet-rich plasma (prp) in the treatment of dark circles under the eyes

Conditions: Periorbital Hyperpigmentation

Summary: 10 ml of blood from each patient will be drawn. this blood specimen will be centrifuged in a specific way to get 1 ml of platelet rich plasma (prp). prp will be injected into the the skin under the eyes. the treatment course consists of three sessions of prp injections with one-month intervals between the sessions.

background: dark circles around the eyes is a common problem pretending with relatively dark eyelids concerns many patients, especially women, because of the inconvenience caused by esthetic and negative impact on the psyche and the patient's quality of life. there are several causing factors (such as sun exposure, smoking, alcohol, sleep deprivation, genetic and structural factors). variety of treatments have been used for this situation , but without clear results. the term 'platelet-rich plasma (prp)' is a general term used to describe hanging plasma that has been obtained from whole blood with concentration of platelets higher than normal concentration found in the circulating blood. prp's work mechanism depends on the fact that platelets contain important substances called (growth factors), which have a known role in the process of reform and renewal of tissues. aim of the research: this study was designed to evaluate the effectiveness of (prp) injection in the treatment of dark circles under the eyes. this is an uncontrolled open therapeutic trial study which will be performed at the hospital of dermatology and venereology of damascus university in damascus, syria during the period from june 2016 to june 2017. the results will be assessed by standardized digital photography month after each injection and three months after the latest assessment with the assistant of skin colors scale. in addition, the patient's satisfaction with the results and any treatment-related side effects will be recorded.

Eligibility criteria:
inclusion criteria: * patients with periorbital hyperpigmentation exclusion criteria: * patients with known platelet dysfunction syndrome * patients with platelet count less than 100,000 ul * patient with hemodynamic instability * patients with severe systemic illness or malignancy or chronic medical illness (e.g. diabetes, chronic infections, and blood dyscrasias). * patients with local skin disorders or active herpes infection at the site of the procedure. * patients on anti-coagulants therapy or non-steroidal anti-inflammatory drugs (nsaid) within 48 hours of procedure, * patients with corticosteroid injection at treatment site within 1 month, systemic use of corticosteroids within 2 weeks * patients with recent fever or illness, and hemoglobin level\< 10 g/dl. * pregnancy * history of keloidal scarring.